{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:07:52Z","timestamp":1790446072100,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2016,5,24]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Evidence that vena cava filters (VCFs) are beneficial is limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>We retrospectively analyzed all noncancer patients admitted to nonfederal California hospitals for acute venous thromboembolism from 2005 to 2010. Analysis was stratified by the presence\/absence of a contraindication to anticoagulation (active bleeding, major surgery). Outcomes were death within 30 or 90 days of admission and the 1-year incidence of recurrent venous thromboembolism manifested as pulmonary embolism or deep vein thrombosis. Propensity score methods were used to account for observed systematic differences in baseline characteristics between patients treated and those not treated with a VCF. Among 80\u2009697 patients with no contraindication to anticoagulation, VCF use (n=7762, 9.6%) did not significantly reduce the 30-day risk of death (hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.98\u20131.28). Among 3017 patients with active bleeding, VCF use (n=1095, 36.3%) reduced the 30-day risk of death by 32% (HR, 0.68; 95% CI, 0.52\u20130.88) and the 90-day risk by 27% (HR, 0.73; 95% CI, 0.59\u20130.90). VCF use (n=489, 33.8%) did not reduce mortality among 1445 patients who underwent major surgery (HR, 1.1; 95% CI, 0.71\u20131.77). In all subgroups, filter use did not reduce the risk of subsequent pulmonary embolism. However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients with no contraindication (HR, 1.53; 95% CI, 1.34\u20131.74) and by 135% among VCF patients with active bleeding (HR, 2.35; 95% CI, 1.56\u20133.52).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>VCF use significantly reduced the short-term risk of death only among patients with acute venous thromboembolism who had a contraindication to anticoagulation because of active bleeding. These results support the findings of a randomized clinical trial and current guidelines that recommend VCF use only in patients who cannot receive anticoagulation treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.115.020338","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T03:53:22Z","timestamp":1459914802000},"page":"2018-2029","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":71,"title":["Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism"],"prefix":"10.1161","volume":"133","author":[{"given":"Richard H.","family":"White","sequence":"first","affiliation":[{"name":"From Division of General Internal Medicine (R.H.W., P.S.R., Z.L.) and Division of Hematology Oncology (A.B., T.W.), Department of Medicine, University of California, Davis School of Medicine, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brunson","sequence":"additional","affiliation":[{"name":"From Division of General Internal Medicine (R.H.W., P.S.R., Z.L.) and Division of Hematology Oncology (A.B., T.W.), Department of Medicine, University of California, Davis School of Medicine, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Romano","sequence":"additional","affiliation":[{"name":"From Division of General Internal Medicine (R.H.W., P.S.R., Z.L.) and Division of Hematology Oncology (A.B., T.W.), Department of Medicine, University of California, Davis School of Medicine, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmin","family":"Li","sequence":"additional","affiliation":[{"name":"From Division of General Internal Medicine (R.H.W., P.S.R., Z.L.) and Division of Hematology Oncology (A.B., T.W.), Department of Medicine, University of California, Davis School of Medicine, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Wun","sequence":"additional","affiliation":[{"name":"From Division of General Internal Medicine (R.H.W., P.S.R., Z.L.) and Division of Hematology Oncology (A.B., T.W.), Department of Medicine, University of California, Davis School of Medicine, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-07-0601"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2725"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.512834"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.316"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.13.2033"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002709900249"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.07.001"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2012.06.005"},{"key":"e_1_3_3_10_2","unstructured":"US Food and Drug Administration. Inferior vena cava (IVC) filters: initial communication: risk of adverse events with long term use. 2010. http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm221707.htm. Accessed March 28 2016."},{"key":"e_1_3_3_11_2","first-page":"1","article-title":"High variation between hospitals in vena cava filter use for venous thromboembolism.","author":"White RH","year":"2013","unstructured":"White RH, Geraghty E, Brunson A, Murin S, Wun T, Spencer F, Romano PS. High variation between hospitals in vena cava filter use for venous thromboembolism. JAMA Intern Med. 2013:1\u20137.","journal-title":"JAMA Intern Med"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3780"},{"key":"e_1_3_3_13_2","unstructured":"Office of Statewide Health Planning and Development. Data request center. http:\/\/www.oshpd.ca.gov\/HID\/Data_Request_Center\/Types_of_Data.html. Accessed March 28 2016."},{"key":"e_1_3_3_14_2","unstructured":"Kassed C Kowlessar N Pfunter A Parlato J Andrews RM The case for the POA indicator: Update 201: ONLINE November 1 2011. U.S. Agency for Healthcare Research and Quality. http:\/\/www.hcupus.ahrq.gov\/reports\/methods\/methods.jsp. Accessed March 28 2016."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.03.009"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318286e34f"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.05.029"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.03.031"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.06.015"},{"key":"e_1_3_3_20_2","unstructured":"Centers for Medicare & Medicaid Services. Appendix E operating room procedures and procedure code\/MS-DRG index. 2014. http:\/\/www.cms.gov\/icd10manual\/fullcode_cms\/P0033.html. Accessed March 28 2016."},{"key":"e_1_3_3_21_2","volume-title":"HCUP comorbidity software","author":"Healthcare Cost and Utilization Project (HCUP)","year":"2008","unstructured":"Healthcare Cost and Utilization Project (HCUP). HCUP comorbidity software. 2008. www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp. Accessed Mar 28, 2016."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1077558707301963"},{"key":"e_1_3_3_23_2","unstructured":"3M Health Information Systems. HCUP all patient refined diagnosis related groups (APR DRGs) version 24.0. methodology overview. 2007. https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/v24_aprdrg_meth_ovrview.pdf. Accessed March 28 2016."},{"key":"e_1_3_3_24_2","first-page":"19","article-title":"Use of the all patient refined-diagnosis related group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU.","volume":"2","author":"Baram D","year":"2008","unstructured":"Baram D, Daroowalla F, Garcia R, Zhang G, Chen JJ, Healy E, Riaz SA, Richman P. Use of the all patient refined-diagnosis related group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Respirat Pulm Med. 2008;2:19\u201325.","journal-title":"Clin Med Circ Respirat Pulm Med"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","unstructured":"Austin PC Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study [published online ahead of print February 3 2014]. Stat Methods Med Res. doi: 10.1177\/0962280213519716. http:\/\/smm.sagepub.com\/content\/early\/2014\/02\/02\/0962280213519716.long. Accessed March 28 2016.","DOI":"10.1177\/0962280213519716"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31806518ac"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.388"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.5283"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5087"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.058"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.075"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.11.003"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.040"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.10.034"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2007.07.010"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.115.020338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:36:29Z","timestamp":1715582189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.115.020338"}},"subtitle":["A Population-Based Study"],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":35,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,5,24]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.115.020338"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.115.020338","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]},"assertion":[{"value":"2015-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}